Featured
Sharper Trial Enrichment for Cardiovascular Outcomes
Using an Aurora prognostic signature to concentrate CV-death events and shrink outcomes trials.
Tom Stubbs, PhD · CEO, Hurdle
Published 28 July 2026
Read the article →
Findings, methods and field notes from the team building diagnostic infrastructure.
Featured
Using an Aurora prognostic signature to concentrate CV-death events and shrink outcomes trials.
Aurora’s discovered CV-death proteins map to established and emerging druggable biology.
Why a proteomic panel predicts cardiovascular death in heart failure far better than NT-proBNP alone.
Five signals from this year's posters, and what they mean for anyone trying to take a biomarker from discovery to the clinic.
Moving beyond binary inclusion and exclusion criteria with ML-driven continuous risk scoring at population scale.
101 articles · page 1 of 9